For lung cancer, the average 5 year survival rate is below 15%-17%. This is largely due to the fact that the disease is detected very late. With early detection and surgical and adjuvant chemotherapy treatment of stage I. to II. cancer, the 5 year survival rate is 25-40% (CRU). BSI started to develop lung cancer diagnostics mAb panel for the early detection of lung cancer. The first version of lung cancer specific mAb panel was purchased by Roche Diagnostics GmbH. A novel lung cancer specific panel on microarray was licensed to Randox Ltd. recently (Randox press release), and finally in 2018 BSI launched it’s QPLC96w blood test on ELISA platform.
